70 related articles for article (PubMed ID: 19145871)
1. [Effect of EGFR (epidermal growth factor receptor) inhibitors on apoptosis and cell proliferation in pancreatic cancer].
Agaev B; Muslimov G; Iagublu V; Geĭdrikh B
Eksp Klin Gastroenterol; 2008; (2):84-90. PubMed ID: 19145871
[No Abstract] [Full Text] [Related]
2. Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model.
El-Metwally TH; Hussein MR; Abd-El-Ghaffar SKh; Abo-El-Naga MM; Ulrich AB; Pour PM
J Clin Pathol; 2006 Jun; 59(6):603-10. PubMed ID: 16473924
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: the study of beta-adrenoceptor antagonist's anticancer effect in pancreatic cancer cell.
Zhang D; Ma Q; Shen S; Hu H
Pancreas; 2009 Jan; 38(1):94-100. PubMed ID: 19106745
[TBL] [Abstract][Full Text] [Related]
4. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
Bergmann F; Breinig M; Höpfner M; Rieker RJ; Fischer L; Köhler C; Esposito I; Kleeff J; Herpel E; Ehemann V; Friess H; Schirmacher P; Kern MA
Am J Gastroenterol; 2009 Jan; 104(1):171-81. PubMed ID: 19098866
[TBL] [Abstract][Full Text] [Related]
5. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
Kim SH; Song YC; Kim SH; Jo H; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
[TBL] [Abstract][Full Text] [Related]
7. Novel apoptosis inducing agents in cancer therapy.
Mita M; Tolcher AW
Curr Probl Cancer; 2005; 29(1):8-32. PubMed ID: 15672328
[No Abstract] [Full Text] [Related]
8. Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells.
Banti I; Nencetti S; Orlandini E; Lapucci A; Breschi MC; Fogli S
J Pharm Pharmacol; 2009 Aug; 61(8):1057-66. PubMed ID: 19703350
[TBL] [Abstract][Full Text] [Related]
9. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
10. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
12. Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin.
Oda A; Katayose Y; Yabuuchi S; Yamamoto K; Mizuma M; Shirasou S; Onogawa T; Ohtsuka H; Yoshida H; Hayashi H; Rikiyama T; Kim H; Choe Y; Kim K; Son H; Motoi F; Egawa S; Unno M
Anticancer Res; 2009 Apr; 29(4):1201-9. PubMed ID: 19414365
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
15. Wilms' tumour gene 1 (WT1) as a target in curcumin treatment of pancreatic cancer cells.
Glienke W; Maute L; Wicht J; Bergmann L
Eur J Cancer; 2009 Mar; 45(5):874-80. PubMed ID: 19196508
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines.
León LG; Giovannetti E; Alecci C; Giancola F; Funel N; Zucali P; Peters GJ; Padrón JM
In Vivo; 2011; 25(2):203-7. PubMed ID: 21471536
[TBL] [Abstract][Full Text] [Related]
17. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2.
Rachid Z; Macphee M; Williams C; Todorova M; Jean-Claude BJ
Bioorg Med Chem Lett; 2009 Sep; 19(18):5505-9. PubMed ID: 19665377
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
20. Peptide YY mediates inhibition of tumor growth and inflammation.
Alosi JA; McFadden DW
Methods Mol Biol; 2009; 512():377-94. PubMed ID: 19347290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
